Piper Sandler on Verona Pharma (VRNA): 'OHTUVAYRE COPD Launch a Blockbuster Opportunity'

July 7, 2025 9:44 AM EDT Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $160.00 price target on Verona Pharma (NASDAQ: VRNA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login